Triple-target polypeptide, derivative, and use thereof
By developing three-target peptides and their derivatives, GLP-1R, GCGR, and GIPR are activated to achieve the effects of lowering blood sugar, lowering blood lipids, and losing weight. Long-lasting effects are achieved through chemical modification, which solves the shortcomings of existing weight loss drugs and meets diverse clinical needs.
WO2026145379A1PCT designated stage Publication Date: 2026-07-09SHANGHAI XITAILI BIOMEDICINE TECHNOLOGY CO LTD
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- SHANGHAI XITAILI BIOMEDICINE TECHNOLOGY CO LTD
- Filing Date
- 2025-12-29
- Publication Date
- 2026-07-09
Smart Images
Figure PCTCN2025146414-FTAPPB-I100001 
Figure PCTCN2025146414-FTAPPB-I100002 
Figure PCTCN2025146414-FTAPPB-I100003
Abstract
Provided is a triple-target polypeptide that exerts glucose-lowering, lipid-lowering, and weight-reducing effects. By rendering the provided triple-target polypeptide long-acting, while retaining the aforementioned excellent effects for specific indications, the advantage of being long-acting is also achieved, which can reduce the frequency of administration, improve the convenience of medication, and enhance patient compliance. Results indicate that the provided polypeptide and a long-acting derivative thereof can significantly lower glucose, lower lipids, and / or reduce weight, and can effectively prevent, treat, or ameliorate diabetes, obesity, obesity-related diseases, or metabolic disorders.
Need to check novelty before this filing date? Find Prior Art